TABLE 6.

Consent for genetic disclosure in the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) sample.

	No	Yes	p value	Effect Size
n	29(10.7%)	242 (89.3%)
Age, years	58.07 (4.2)	58.73 (4.6)	0.44	0.15
Education, years	15.10(2.5)	15.42 (2.4)	0.52	0.13
Gender, % female	48.3%	47.5%	0.94	0.005
Race (n of Yes/No within racial/ethnicgroup), %			0.63	0.10
Non-Hispanic White	29(11.6%)	220 (88.4%)
Hispanic	0 (0%)	8 (100%)
Black/African American	0 (0%)	9 (100%)
Asian	0 (0%)	3 (100%)
More than one race	0 (0%)	2 (100%)
Diagnostic group (n of Yes/No within diagnostic group), %			0.28	0.07
CN	N/A	N/A
EOnonAD	5 (7.3%)	64 (92.7%)
EOAD	24(11.9%)	178 (88.1%)
Mini-Mental State Examination	22.97 (5.4)	22.79 (5.1)	0.87	0.03

Note: Gender reflects the percent of participants within either the Yes or No group that were female. Values for age, education, and Mini-Mental State Examination represent the mean and interquartile range. Gender reflects the percent of participants within either the Yes or No group that were female. Race reflects the number and percent of participants within a particular racial/ethnic category that did or did not provide consent for genetic disclosure. Diagnostic Group reflects the number and percent of participants within a specific diagnostic group that did or did not provide consent for genetic disclosure. p values reflect results of t-tests (for continuous variables) and chi-square analyses (for categorical variables) comparing Yes and No groups. Effect Sizes were calculated using Cohen's d for continuous variables and Cohen's wfor categorical variables.

Abbreviations: CN, cognitively normal; No, did not provide consent for lumbar puncture; Yes, provided consent for lumbar puncture; EOnonAD, early-onset non-Alzheimer's disease; EOAD, early-onset Alzheimer's disease; LEADS, Longitudinal Early-Onset Alzheimer's Disease Study; MMSE, Mini-Mental State Examination.